Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1

A novel series of potent diacylglycerol acyl transferase 1 inhibitors was developed from the clinical candidate AZD3988. Replacement of the phenyl cyclohexyl-ethanoate side chain with substituted oxy-linked side chains to introduce changes in shape and polarity, reduce lipophilicity and mask the hydrogen bond donors with internal hydrogen bond acceptors led to improvements in solubility, unbound clearance and excellent selectivity over the related enzyme acyl-coenzyme A:cholesterol acyltransferase 1. A comparison of the small molecule crystal structures of compound 4 and compound 28 is described. Compounds in this series have good ADMET properties and provide an exposure-dependent decrease in circulating plasma triglyceride levels in a rat oral lipid tolerance test.

[1]  Andrew G. Leach,et al.  Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. , 2012, Bioorganic & medicinal chemistry letters.

[2]  Steven C. Cullen,et al.  Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1. , 2012, Journal of medicinal chemistry.

[3]  A. Vulpetti,et al.  Intermolecular and Intramolecular Hydrogen Bonds Involving Fluorine Atoms: Implications for Recognition, Selectivity, and Chemical Properties , 2012, ChemMedChem.

[4]  Jonas Boström,et al.  Oxadiazoles in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[5]  M. Munchhof,et al.  Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. , 2011, Bioorganic & medicinal chemistry letters.

[6]  Eliot Sugarman,et al.  Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. , 2011, ACS medicinal chemistry letters.

[7]  David Buttar,et al.  A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. , 2010, Bioorganic & medicinal chemistry.

[8]  Catherine C. Y. Chang,et al.  Acyl-coenzyme A:cholesterol acyltransferases. , 2009, American journal of physiology. Endocrinology and metabolism.

[9]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[10]  Peter W. Kenny,et al.  Hydrogen Bonding, Electrostatic Potential, and Molecular Design , 2009, J. Chem. Inf. Model..

[11]  A. Turnbull,et al.  Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. , 2009, Journal of medicinal chemistry.

[12]  A. Turnbull,et al.  Diacylglycerol acyltransferases: Potential roles as pharmacological targets. , 2008, Pharmacology & therapeutics.

[13]  I. Enyedy,et al.  Antisense and small-molecule modulation of diacylglycerol acyltransferase , 2007 .

[14]  Robert V Farese,et al.  Atvb in Focus Novel Approaches to the Treatment of Dyslipidemia Inhibition of Triglyceride Synthesis as a Treatment Strategy for Obesity Lessons from Dgat1-deficient Mice Dgat Enzymes and Triglyceride Synthesis , 2022 .

[15]  T. Voelker,et al.  DGAT2 Is a New Diacylglycerol Acyltransferase Gene Family , 2001, The Journal of Biological Chemistry.

[16]  P. C. Hariharan,et al.  The influence of polarization functions on molecular orbital hydrogenation energies , 1973 .

[17]  Peter W. Kenny,et al.  Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field analysis , 1994 .